Home Blog of Signal Transduction Microbiology SARS-CoV Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19

Background: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication in vitro.

Materials & methods: Adults in hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two parts after interim analysis; part B enrollment limited owing to evolving standard of care.

Results: Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause mortality. Compared with placebo, bemnifosbuvir treatment resulted in 0.61 log10 greater viral load mean change on day 2; trend sustained through day 8. Treatment-emergent adverse events were similar in both groups; most were mild/moderate, unrelated to study drug.

Conclusion: Our results suggest a potential role for bemnifosbuvir in blunting COVID-19 progression.

 

Comments:

It sounds like the study on bemnifosbuvir showed some interesting results, despite not meeting its primary efficacy endpoint. The drug seemed well tolerated and didn't contribute to increased mortality among participants. Although the study ended prematurely, there was a notable decrease in viral load compared to the placebo group, indicating a potential for bemnifosbuvir to impede COVID-19 progression.

The observed trend of reduced viral load from day 2 through day 8 suggests some efficacy in controlling the virus. Additionally, the similarity in treatment-emergent adverse events between the bemnifosbuvir and placebo groups, mostly being mild or moderate and unrelated to the study drug, implies a good safety profile for bemnifosbuvir.

Even though the study didn't meet its primary goal, these findings could still indicate a promising direction for further research or potential use of bemnifosbuvir in managing moderate COVID-19 cases.

Related Products

Cat.No. Product Name Information
E1013 Bemnifosbuvir Hemisulfate (AT-527)

Bemnifosbuvir Hemisulfate (AT-527, RG-6422, RO 7496998) is a hemi-sulfate salt of AT-511. AT-511 is a potent inhibitor of SARS-CoV-2 with an EC90 of 0.47 μM.

Related Targets

SARS-CoV